Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Medical Tourism Experts

Joe Atkins, RN, MBA, CNN, CHT, Chief Executive Officer
Medical Concepts & Innovations
Analysis of: The Price of Excess: Identifying Waste in Healthcare Spending (blogs.wsj.com)
It's easy to point fingers of blame and this article does that, very well.  According to the "annalysis" everybody is to blame.  And, they're right, everyone is to blame, but where the article fails is the authoris inability to point out a real solution to the problem of wasted dollars spent...
Joe Atkins, RN, MBA, CNN, CHT, Chief Executive Officer
Medical Concepts & Innovations
Analysis of: WellPoint likely to follow FDA on anemia drugs (www.reuters.com)
Over the last year, it has become clear that the over-use of anemia drugs for cancer and renal failure has become a problem.  The reason can be sumed up in one word, which is profit.
Analysis of: The Price of Excess--Identifying Waste in Healthcare Spending (www.pwc.com)
For the first time a major comprehensive authoritative national study (by PricewaterhouseCoopers, LLP) has concluded that over one half of the nation's $2.2 trillion in annual health spending (fully $1.2 trillion) is wasted.  Other studies have put this percentage in the 25 to 40% range. ...
April 24, 2008
IL-13 in asthma
Analysis of: MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13 (www.pipelinereview.com)
This is a better target than IL-5.  But some of the issues are the same.
Analysis of: Pluristem's PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model (www.pipelinereview.com)
The battle between hype and hope continues.
April 24, 2008
Lexicon's drug for RA
Analysis of: Lexicon's Drug Candidate for Rheumatoid Arthritis, LX2931, Shows Positive Results in Phase 1 Clinical Trial (www.pipelinereview.com)
To call these result positive is to be very optimistic.
Analysis of: CimziaA(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease (www.pipelinereview.com)
Another anti-TNF for Crohns Disease.  How will it stack up against the competition?
Richard Baland, Partner
Richard Baland, Partner
B2B CFO
Analysis of: University Hospitals in Cleveland makes aggressive refinancing move (blog.cleveland.com)
Increasing interest rates and debt service, a Decrease in available cash, a Migration to more fixed rate borrowing and appeals to state governments for assistance, a delay in physical plant additions/upgrades
Analysis of: Feds Try to Cut the Costs of Hospital Errors (www.forbes.com)
The Medicare Program stunned much of the hospital world last year when they stated that beginning in October, 2008 (Federal Fiscal Year 2009) it would no longer pay for the costs Medicare patients generated for their treatment of eight conditions not present on admission which were likely the result...
April 15, 2008
Big Pharma's future
Analysis of: Where The Jobs Aren’t: Research & Development (www.pharmalot.com)
To paraphrase, rumors of big pharma's demise are vastly exaggerated.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next71 to 80 of 667

Analytics


Generated at 2009-01-07T19:00:58.307